Least developed countries vs Tunisia: Immunization, Hib3
Immunization, Hib3 over time
- Least developed countries
- Tunisia
How they compare
Tunisia currently reports 97.0% against 74.4% in Least developed countries, a difference of 22.6%.
That makes Tunisia's figure about 1.3 times Least developed countries's.
The two have swapped places 2 times across 17 shared years of data; in 2003 it was Tunisia ahead.
Least developed countries ranks 30th and Tunisia ranks 29th of 43 groups.
Tunisia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Least developed countries | Tunisia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 8.0% | 91.0% | 83.0% | Tunisia |
| 2010s | 76.2% | 91.7% | 15.4% | Tunisia |
| 2020s | 74.4% | 97.0% | 22.6% | Tunisia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Least developed countries or Tunisia?
- Tunisia, at 97.0% against 74.4% in Least developed countries as of 2024.
- What is the difference in immunization, hib3 between Least developed countries and Tunisia?
- 22.6%, with Tunisia ahead.
- How many years of comparable data are there for Least developed countries and Tunisia?
- 17 years are reported by both, from 2003 to 2024.
- How do Least developed countries and Tunisia rank globally for immunization, hib3?
- Least developed countries ranks 30th and Tunisia ranks 29th of 43 groups.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.